Exploratory analysis of prognostic factors for lenvatinib in radioiodine‐refractory differentiated thyroid cancer

C Suzuki, N Kiyota, Y Imamura, H Goto, H Suto… - Head & …, 2019 - Wiley Online Library
Background Multitarget kinase inhibitors (m‐TKI), including lenvatinib, are now available as
treatment options for radioiodine‐refractory differentiated thyroid cancer (RR‐DTC) …
被引用次数：36 相关文章

Exploratory analysis of prognostic factors for lenvatinib in radioiodine‐refractory differentiated thyroid cancer.

C Suzuki, N Kiyota, Y Imamura, H Goto, H Suto… - Head & …, 2019 - search.ebscohost.com
Background: Multitarget kinase inhibitors (m‐TKI), including lenvatinib, are now available as
treatment options for radioiodine‐refractory differentiated thyroid cancer (RR‐DTC) …

Exploratory analysis of prognostic factors for lenvatinib in radioiodine‐refractory differentiated thyroid cancer

C Suzuki, N Kiyota, Y Imamura, H Goto, H Suto… - Head & Neck, 2019 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: sec>< jats: title> Background</jats: title>< jats: p>
Multitarget kinase inhibitors (m‐TKI), including lenvatinib, are now available as treatment …

Exploratory analysis of prognostic factors for lenvatinib in radioiodine-refractory differentiated thyroid cancer.

C Suzuki, N Kiyota, Y Imamura, H Goto, H Suto… - Head & …, 2019 - europepmc.org
Background Multitarget kinase inhibitors (m-TKI), including lenvatinib, are now available as
treatment options for radioiodine-refractory differentiated thyroid cancer (RR-DTC) …

Exploratory analysis of prognostic factors for lenvatinib in radioiodine-refractory differentiated thyroid cancer

C Suzuki, N Kiyota, Y Imamura, H Goto… - Head & …, 2019 - pubmed.ncbi.nlm.nih.gov
Background Multitarget kinase inhibitors (m-TKI), including lenvatinib, are now available as
treatment options for radioiodine-refractory differentiated thyroid cancer (RR-DTC) …